Figure 7.

High CISAL and Low BRCA1 Expression Correlates with Favorable Neoadjuvant Chemosensitivity and Prognosis in TSCC Patients

(A) CISAL and BRCA1 expression and apoptosis were compared in chemosensitive and nonsensitive TSCC tumor samples. CISAL and BRCA1 expression was analyzed by ISH and IHC (×200), respectively; apoptosis was detected using TUNEL assays; scale bar, 20 μm.

(B) Quantification of CISAL and BRCA1 expression in chemosensitive and nonsensitive TSCC tumors; ***p<0.001, 2-tailed Student's t test.

(C) Associations of CISAL and BRCA1 expression in TSCC analyzed by Spearman rank order correlation.

(D) Kaplan-Meier survival curves for TSCC patients were plotted for CISAL and BRCA1 expression, and survival differences were analyzed using a logrank test.

(E) Schematic representation of our proposed model of direct interaction of CISAL with BRCA1 promoter to sequester the downstream GABPA away from transcriptional regulatory binding sites, silencing BRCA1 transcription, subsequently upregulating mitochondrial fission and cisplatin sensitivity in carcinoma cells.